Journal of Personalized Medicine,
Journal Year:
2023,
Volume and Issue:
13(10), P. 1460 - 1460
Published: Oct. 4, 2023
Background:
A
malfunction
in
the
melanocortin-4
receptor
(MC4R)
is
associated
with
obesity
rare
genetic
syndromes;
setmelanotide
a
new
drug
that
activates
this
and
being
used
to
treat
severe
obesity.
This
meta-analysis
evaluated
efficacy
safety
of
for
weight
loss
linked
human
MC4R
deficiency.
Methods:
We
searched
PubMed,
Embase,
Cochrane
randomized
nonrandomized
clinical
trials
using
setmelanotide.
considered
p-value
≤
0.05
statistically
significant.
Results:
included
376
patients,
whom
328
(87.2%)
received
mean
follow-up
52
weeks.
The
age
was
32.8
(14.67)
years.
Weight
significant
(MD
−3.52;
95%
CI
−3.98,
−3.05;
p
=
0.01;
I2
92%),
an
average
proportion
−6.91%
during
treatment.
Changes
BMI
showed
MD
−10.55
kg/m2
patients
>
18
years
−0.61
<
(BMI
score).
However,
higher
risk
skin
hyperpigmentation
(OR
0.69;
0.55,
0.80;
0.08).
Conclusions:
Our
results
support
use
treating
MedComm,
Journal Year:
2024,
Volume and Issue:
5(6)
Published: May 24, 2024
Abstract
White
adipose
tissue
is
not
only
a
highly
heterogeneous
organ
containing
various
cells,
such
as
adipocytes,
stem
and
progenitor
immune
but
also
an
endocrine
that
important
for
regulating
metabolic
homeostasis.
In
individuals
with
obesity,
dynamic
cellular
changes
in
result
phenotypic
switching
dysfunction,
including
pathological
expansion,
WAT
fibrosis,
cell
infiltration,
endoplasmic
reticulum
stress,
ectopic
lipid
accumulation,
ultimately
leading
to
chronic
low‐grade
inflammation
insulin
resistance.
Recently,
many
distinct
subpopulations
of
have
been
identified,
providing
new
insights
into
the
potential
mechanisms
dysfunction
obesity.
Therefore,
targeting
white
therapeutic
agent
treating
obesity
obesity‐related
diseases
great
scientific
interest.
Here,
we
provide
overview
remodeling
discuss
underlying
regulatory
dysfunction.
Currently,
studies
uncovered
promising
targets
strategies
treatment.
We
outline
signaling
pathways
summarize
existing
antiobesity
treatment
pharmacological
approaches,
lifestyle
interventions,
novel
therapies.
Diabetes Obesity and Metabolism,
Journal Year:
2024,
Volume and Issue:
26(6), P. 2446 - 2455
Published: March 26, 2024
Abstract
Aims
To
describe
the
overall
fat
distribution
patterns
independent
of
body
mass
index
(BMI)
in
participants
with
type
2
diabetes
(T2D)
SURPASS‐3
MRI
substudy
by
comparison
sex‐
and
BMI‐matched
virtual
control
groups
(VCGs)
derived
from
UK
Biobank
imaging
study
at
baseline
Week
52.
Methods
For
each
participant
52
(
N
=
296),
a
VCG
≥150
same
sex
similar
BMI
was
identified
40
172).
Average
visceral
adipose
tissue
(VAT),
abdominal
subcutaneous
(aSAT)
liver
(LF)
levels
observed
standard
deviations
(SDs;
standardized
normal
z
‐scores:
‐VAT,
‐aSAT
‐LF)
were
calculated
based
on
matched
VCGs.
Differences
‐scores
between
to
potential
shifts
pattern
weight
change.
Results
Baseline
across
pooled
tirzepatide
(5,
10
15
mg)
insulin
degludec
(IDeg)
arms.
Compared
VCGs,
had
higher
VAT
(mean
[SD]
‐VAT
+0.42
[1.23];
p
<
0.001)
LF
‐LF
+1.24
[0.92];
but
aSAT
−0.13
[1.11];
0.083).
Tirzepatide‐treated
significant
decreases
(−0.18
[0.58];
(−0.54
[0.84];
increased
(+0.11
[0.50];
0.012).
Participants
treated
IDeg
change
only
(−0.46
[0.90];
0.001),
while
no
changes
for
(+0.13
[0.52];
0.096)
(+0.09
[0.61];
0.303).
Conclusion
In
this
exploratory
analysis,
treatment
people
T2D
resulted
reduction
‐LF,
an
initially
negative
value,
suggesting
possible
treatment‐related
shift
towards
more
balanced
prominent
loss.
Journal of Personalized Medicine,
Journal Year:
2023,
Volume and Issue:
13(10), P. 1460 - 1460
Published: Oct. 4, 2023
Background:
A
malfunction
in
the
melanocortin-4
receptor
(MC4R)
is
associated
with
obesity
rare
genetic
syndromes;
setmelanotide
a
new
drug
that
activates
this
and
being
used
to
treat
severe
obesity.
This
meta-analysis
evaluated
efficacy
safety
of
for
weight
loss
linked
human
MC4R
deficiency.
Methods:
We
searched
PubMed,
Embase,
Cochrane
randomized
nonrandomized
clinical
trials
using
setmelanotide.
considered
p-value
≤
0.05
statistically
significant.
Results:
included
376
patients,
whom
328
(87.2%)
received
mean
follow-up
52
weeks.
The
age
was
32.8
(14.67)
years.
Weight
significant
(MD
−3.52;
95%
CI
−3.98,
−3.05;
p
=
0.01;
I2
92%),
an
average
proportion
−6.91%
during
treatment.
Changes
BMI
showed
MD
−10.55
kg/m2
patients
>
18
years
−0.61
<
(BMI
score).
However,
higher
risk
skin
hyperpigmentation
(OR
0.69;
0.55,
0.80;
0.08).
Conclusions:
Our
results
support
use
treating
